Werewolf Therapeutics (HOWL) Registration Filing summary

Company overview and business model

• Pioneers therapeutics that stimulate the immune system for cancer and immune-mediated conditions using the proprietary PREDATOR™ platform and INDUKINE™ molecules, with lead candidates WTX-124 (IL-2) and WTX-330 (IL-12) targeting multiple tumor types.

• Incorporated in Delaware in 2017, with principal offices in Watertown, MA.

Financial performance and metrics

• As of May 8, 2025, public float was approximately $37.4 million, with 44,873,646 shares outstanding and 29,686,472 held by non-affiliates.

• Last reported sale price of common stock on May 7, 2025, was $0.92 per share.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, including R&D, clinical trials, acquisitions or in-licensing, collaborations, working capital, and capital expenditures.

• Proceeds may be temporarily invested in short-term, investment-grade instruments and U.S. government securities.